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Immunodeficiency Virus–Infected Inpatients Meeting the 
Criteria of Seriously Ill in the World Health Organization 
Algorithm
Rulan Griesel,1 Annemie Stewart,1 Helen van der Plas,2 Welile Sikhondze,2 Molebogeng X. Rangaka,3,4,5 Mark P. Nicol,6,7 Andre P. Kengne,3,8 
Marc Mendelson,2,a and Gary Maartens1,a
1Division of Clinical Pharmacology, 2Division of Infectious Diseases and HIV Medicine, and  3Department of Medicine, University of Cape Town, South Africa; 4Institute of Global Health, Department 
of Infection and Population Health, University College London, United Kingdom;  5Institute of Infectious Disease and Molecular Medicine and 6Division of Medical Microbiology, Department of 
Pathology, University of Cape Town,  7National Health Laboratory Service of South Africa, Cape Town, and 8Medical Research Council, Cape Town, South Africa
Background. The World Health Organization (WHO) algorithm for the diagnosis of tuberculosis in seriously ill human im-
munodeficiency virus (HIV)–infected patients lacks a firm evidence base. We aimed to develop a clinical prediction rule for the 
diagnosis of tuberculosis and to determine the diagnostic utility of the Xpert MTB/RIF assay in seriously ill HIV-infected patients.
Methods. We conducted a prospective study among HIV-infected inpatients with any cough duration and WHO-defined danger 
signs. Culture-positive tuberculosis from any site was the reference standard. A priori selected variables were assessed for univariate 
associations with tuberculosis. The most predictive variables were assessed in a multivariate logistic regression model and used to 
establish a clinical prediction rule for diagnosing tuberculosis.
Results. We enrolled 484 participants. The median age was 36 years, 65.5% were female, the median CD4 count was 89 cells/
µL, and 35.3% were on antiretroviral therapy. Tuberculosis was diagnosed in 52.7% of participants. The c-statistic of our clinical pre-
diction rule (variables: cough ≥14 days, unable to walk unaided, temperature >39°C, chest radiograph assessment, hemoglobin, and 
white cell count) was 0.811 (95% confidence interval, .802–.819). The classic tuberculosis symptoms (fever, night sweats, weight loss) 
added no discriminatory value in diagnosing tuberculosis. Xpert MTB/RIF assay sensitivity was 86.3% and specificity was 96.1%.
Conclusions. Our clinical prediction rule had good diagnostic utility for tuberculosis among seriously ill HIV-infected inpatients. 
Xpert MTB/RIF assay, incorporated into the updated 2016 WHO algorithm, had high sensitivity and specificity in this population. 
Our findings could facilitate improved diagnosis of tuberculosis among seriously ill HIV-infected inpatients in resource-constrained 
settings.
Keywords. HIV; tuberculosis diagnosis; WHO algorithm; inpatients; Xpert MTB/RIF assay.
 
Tuberculosis remains a major cause of death among human 
immunodeficiency virus (HIV)–infected adults in resource-con-
strained countries in the antiretroviral therapy (ART) era [1]. 
Delayed or missed diagnosis contributes to tuberculosis mor-
tality [2, 3]. World Health Organization (WHO) 2007 guide-
lines to diagnose smear-negative tuberculosis [4] included an 
algorithm for seriously ill patients with cough of 2–3 weeks and 
≥1 danger sign (respiratory rate >30 breaths/minute, heart rate 
>120 beats/minute, temperature >39°C, and being unable to 
walk unaided).
A modified WHO algorithm for seriously ill patients improved 
clinical outcomes in 2 African cohort studies [5, 6]. However, 
no study has explored the ability of the 2007 WHO seriously 
ill algorithm to diagnose tuberculosis, which has several limi-
tations. First, pulmonary tuberculosis commonly presents with 
cough duration of <14 days [7, 8]. Second, other classic tuber-
culosis symptoms (fever, night sweats, and weight loss), which 
have high negative predictive value in active case finding [9], 
were not included. Third, it preceded the Xpert MTB/RIF assay, 
which is more sensitive than smear microscopy in HIV-infected 
patients [10]. Finally, hemoglobin concentration and white cell 
count (WCC), which predict tuberculosis among HIV-infected 
patients [11–13], could add diagnostic value.
We conducted a prospective cohort study to attempt to improve 
the ability of the 2007 WHO algorithm to diagnose tuberculosis 
in seriously ill HIV-infected patients by evaluating any cough 
duration, classic tuberculosis symptoms, chest radiographic fea-
tures, hemoglobin, WCC, and the Xpert MTB/RIF assay.
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METHODS
Study Population
We conducted a prospective cohort study in 2 regional hos-
pitals in Cape Town, South Africa serving high-burden HIV 
and tuberculosis communities, GF Jooste Hospital (November 
2011–February 2013) and Khayelitsha District Hospital (March 
2013–October 2014). Inclusion criteria were as follows: HIV 
infected, ≥18 years of age, admitted within 24 hours, coughing 
for any duration, and ≥1 WHO danger sign. Exclusion crite-
ria were antituberculosis therapy that is current or completed 
in the previous month or defaulted within the past 6 months, 
exacerbation of cardiac failure or chronic obstructive pulmo-
nary disease, and inability to produce a spontaneous or induced 
sputum sample. Participants were followed up at 28 and 56 days 
after discharge.
Data Collection
Demographic data and clinical features (at the time of admis-
sion) were recorded on a standardized case record form. Chest 
radiographs performed on admission were assessed by the study 
medical officer for features suggestive of pulmonary tubercu-
losis and/or bacterial pneumonia and/or Pneumocystis jirovecii 
pneumonia (PJP). Chest radiographs were also retrospectively 
reviewed by a blinded specialist radiologist, who documented 
the presence of specific radiographic features (enlarged hilar or 
mediastinal lymph nodes, pleural effusions, interstitial (“ground 
glass”) infiltration, nodularity, cavitation, diffuse micronodular 
infiltration, linear/reticulonodular infiltration, consolidation, 
and features of previous tuberculosis), and then classified radi-
ographs as likely, possible, or unlikely for pulmonary tubercu-
losis and/or bacterial pneumonia and/or PJP. CD4 cell count 
was obtained on admission if none was available from the prior 
6 months, and hemoglobin and WCC were done on admission. 
Sputum induction, using an ultrasonic nebulizer and hyper-
tonic saline, was done on participants unable to spontaneously 
produce sputum. Three sputum samples from each participant 
were sent for Gram stain, culture, and sensitivity (1 sample); 
and auramine smear microscopy for acid-fast bacilli, and myco-
bacterial culture (BACTEC MGIT 960; Becton Dickinson, 
Franklin Lakes, New Jersey) (2 samples). The sputum pellet on 
one of the samples for mycobacterial culture was split after de-
contamination for Xpert MTB/RIF assay (Cepheid, Sunnyvale, 
California). Mycobacterial blood cultures (BacT/Alert MP; 
bioMérieux, Durham, North Carolina) were sent from all par-
ticipants. Extrapulmonary samples (eg, pleural fluid) were sent 
for mycobacterial culture when appropriate.
Case Definitions and Procedures
Tuberculosis was defined as a positive culture for Mycobacterium 
tuberculosis from any site. The study criteria for initiating antitu-
berculosis therapy included positive microbiological diagnosis 
(auramine stain and/or Xpert MTB/RIF assay and/or culture); 
and/or a radiological diagnosis (chest radiograph showing me-
diastinal and/or hilar lymph nodes or miliary infiltrates; ab-
dominal ultrasound showing multiple enlarged lymph nodes 
and/or multiple splenic hypoechoic lesions and/or pericardial 
effusion); and/or pleural effusion/ascites showing a lympho-
cytic exudate; and/or no clinical improvement after 3–5  days 
of antibiotic therapy. Decisions to start antituberculosis therapy 
were made by study staff.
The diagnosis of bacterial pneumonia was made with con-
sistent symptoms and evidence of consolidation on chest radio-
graph. Bacterial pneumonia was treated with a broad-spectrum 
β-lactam antibiotic (eg, ceftriaxone, amoxicillin-clavulanate), 
and a macrolide was added with CRB-65 score >2 (1 point for 
each of: confusion, respiratory rate ≥30/min, blood pressure sys-
tolic <90 mm Hg or diastolic ≤60 mm Hg, age ≥65 years [14, 15].
PJP was diagnosed with a cough duration ≤12 weeks, bilat-
eral interstitial infiltration on chest radiograph, and hypoxia 
(defined as oxygen saturation of ≤92%) or dyspnea. PJP was 
treated with high-dose trimethoprim-sulfamethoxazole, and 
prednisone if hypoxia was present.
Statistical Analysis
A sample size of 473 was sufficient to detect an estimated 
30% prevalence of culture-positive tuberculosis with 5% pre-
cision. This sample size incorporated the need for at least 10 
culture-positive tuberculosis events per predictive variable for 
multivariate logistic regression analysis [16].
Analyses were performed using Stata version 12.1 software 
(StataCorp, College Station, Texas). Missing data were imputed 
using chained equations and 20 iterations. Baseline characteristics 
were described as proportions or medians. We used univariate 
associations to assess the ability of the following a priori selected 
variables to predict tuberculosis: age, sex, cough duration, indi-
vidual WHO danger signs, classic tuberculosis symptoms (fever, 
night sweats, and weight loss), radiologist assessment of tuber-
culosis on chest radiograph (categorized as likely or possible), 
hemoglobin, and WCC [17]. A backward stepwise approach 
proposed by Collet [18] was used to select the most predictive 
variables in establishing a multivariate logistic regression model.
The model was visually assessed by a calibration plot, and 
by the Hosmer–Lemeshow test. An estimate of the c-statistic 
was used to assess discrimination (values 0.7–0.8 are deemed 
acceptable and 0.8–0.9 good) [19]. Internal validation used 1000 
bootstrap resamples [20]. A clinical prediction rule with score 
chart was constructed utilizing a standard method [21]. We used 
the clinical prediction rule to predict the probability of having 
tuberculosis, and compared it with the reference standard of cul-
ture-positive tuberculosis. We calculated the diagnostic accuracy 
for the range of possible scores from the clinical prediction rule.
We explored associations of individual chest radiograph fea-
tures recorded by the radiologist with culture-positive tuberculo-
sis, reported as odds ratios with 95% confidence intervals (CIs). 
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We calculated the diagnostic accuracy of sputum smear and Xpert 
MTB/RIF assay for diagnosing culture-positive tuberculosis.
Ethics Approval
Approval for the study was obtained from the University of 
Cape Town Human Research Ethics Committee. All eligible 
participants signed informed consent before enrollment into 
the study. Confused participants were enrolled and given the 
option to continue with participation once orientated; their 
data were removed from the study if consent was declined.
RESULTS
Participant Characteristics
We screened 2054 patients and enrolled 484 (Figure 1). Table 1 
shows participants’ baseline characteristics. All participants 
were commenced on antibiotic therapy at admission or at the 
referral site. Fifty-three percent (255/484) of participants had 
culture-positive tuberculosis, 50.6% (245/484) bacterial pneu-
monia, and 10.5% (51/484) PJP. Antituberculosis therapy was 
empirically started in 56 (11.6%) participants with negative spu-
tum smears and Xpert MTB/RIF assays, of whom 22 (43.1%) had 
culture-positive tuberculosis. Other diagnoses (Cryptococcus 
neoformans, Emmonsia parva, nontuberculous mycobacteria, 
and malignancy) were made in 8.5% (41/484). Clinically diag-
nosed coinfections were common: tuberculosis with bacter-
ial pneumonia in 25.8% (125/484) and tuberculosis with PJP 
in 4.3% (21/484). Different sites of culture-positive specimens 
(Supplementary Table 1) and pulmonary/extrapulmonary/dis-
seminated tuberculosis are given in the Supplementary Data. 
The diagnostic accuracy of Xpert MTB/RIF assay and smear is 
shown in Table 2.
The yield of sputum culture was higher with sputum induc-
tion than spontaneous sputum production (56.1% [175/312] 
vs 45.5% [74/163]; P = .027). Similarly, the yield of smear and 
Xpert MTB/RIF assay was higher with sputum induction than 
spontaneous sputum production (32.7% [102/312] vs 30.1% 
[49/163], P  =  .553 and 51.9% [162/312] vs 41.7% [68/163], 
P = .035, respectively).
Seventy-two participants with negative sputum smears had 
features of tuberculosis on chest radiograph diagnosed by med-
ical officers, fulfilling the criteria of the 2007 WHO algorithm 
for seriously ill inpatients to start empiric antituberculosis 
therapy with a sensitivity of 49.1% and specificity of 91.5% for 
the diagnosis of culture-positive tuberculosis.
Clinical Prediction Rule
Univariate  associations with culture-positive tuberculo-
sis are shown in Table 3. In multivariate logistic regression 
(Supplementary Table 2) the most significant predictors of cul-
ture-positive tuberculosis were being unable to walk unaided, 
radiologist assessment of “likely tuberculosis” on chest radi-
ograph, and anemia. Raised WCC was a significant negative 
predictor of tuberculosis. The only classic tuberculosis symp-
tom that showed a significant association with the diagnosis of 
tuberculosis was weight loss, but it was not significant on mul-
tivariate analysis. Cough duration ≥14 days was predictive of 
tuberculosis, but 28.6% (73/255) of culture-positive tuberculo-
sis participants had cough duration <14 days.
The calibration curve (Figure 2A) for the final model fol-
lowed the ideal calibration line, indicating good agreement be-
tween the rate of tuberculosis estimated by the model and the 
tuberculosis frequency observed in the study population, con-
firmed by the Hosmer-Lemeshow χ
2
 statistic of 10.65 (P = .385). 
The model’s c-statistic was 0.834 (95% CI, .798–.871) (Figure 
2B). The equivalents in bootstrap validation were 0.836 (95% 
CI, .800–.871), with an optimism estimate of 0.011 (95% CI, 
.010–.012), indicating good stability of the model in internal 
validation.
The clinical prediction rule with score chart was developed 
using the 6 selected variables (Table 4). Hemoglobin and WCC 
were categorized as tertiles. The diagnostic accuracy assessment 
based on different scores obtained from the clinical predic-
tion rule is summarized in Table 5. The clinical prediction rule 
model showed a c-statistic of 0.811 (95% CI, .802–.819).
Chest Radiograph Assessment
The radiologist assessed 416 participants’ chest radiographs: 





484 had ≥1 
danger signs
Tuberculosis treatment
      653 currently using
      30 recently completed
      50 recently defaulted 







128 no danger signs
28 with COPD exacerbation
24 with CCF exacerbation
26 no sputum samples 
obtained 
Figure 1. Flow diagram for participant inclusion into the study. Abbreviations: 
CCF, congestive cardiac failure; COPD, chronic obstructive pulmonary disease; HIV, 
human immunodeficiency virus.
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and 42 (10.0%) as unlikely tuberculosis. Univariate analysis 
of individual chest radiograph features revealed that diffuse 
micronodular infiltration, enlarged hilar or mediastinal lymph 
nodes, and nodularity >3 mm were predictors of culture-pos-
itive tuberculosis (Table 6). Bacterial pneumonia was a likely 
diagnosis in 9.6% (40/416) and PJP in 9.4% (39/416). Medical 
officers’ categorization of likely tuberculosis on chest radi-
ograph had an odds ratio of 9.4 (95% CI, 5.7–15.6) for cul-
ture-positive tuberculosis.
DISCUSSION
Our study is the first to evaluate the clinical, radiographic, and 
laboratory diagnosis of tuberculosis in a prospective cohort of 
Table  2. Diagnostic Accuracy Evaluation of Sputum Auramine Smear 
and Xpert MTB/RIF Assay by the Reference Standard of Positive Culture 
From Any Site (n = 255) Among 484 Seriously Ill Human Immunodeficiency 
Virus–Infected Participants Presenting With a Cough of Any Duration and 
≥1 World Health Organization Danger Sign
Parameter Xpert MTB/RIF Auramine Smear
Sensitivity, % 86.3 (81.5–90.3) 57.0 (50.7–63.2)
Specificity, % 96.1 (92.6–98.2) 98.7 (96.2–99.7)
Positive predictive value, % 96.1 (92.7–98.2) 98.0 (94.2–99.6)
Negative predictive value, % 86.2 (81.4–90.2) 67.2 (61.9–72.2)
Positive likelihood ratio 21.9 (11.5–41.6) 43.3 (14.0–134.0)
Negative likelihood ratio 0.14 (.11–.19) 0.44 (.38–.50)
Values in parentheses indicate the 95% confidence interval.
Table  3. Univariate Associations With Culture-Positive Tuberculosis 
Among 484 Seriously Ill Human Immunodeficiency Virus–Infected 
Participants Presenting With a Cough of Any Duration and ≥1 World Health 
Organization Danger Sign
Variable OR (95% CI) Wald P Value
Agea 0.98 (.96–1.00) .044
Sex
 Female Referent group
 Male 0.95 (.65–1.39) .799
Cough duration ≥14 d
 No Referent group
 Yes 2.47 (1.70–3.60) <.001
WHO danger signs
 Respiratory rate >30 breaths/min
  No Referent group
  Yes 0.78 (.54–1.14) .207
 Heart rate >120 beats/min
  No Referent group
  Yes 1.53 (.98–2.37) .060
 Temperature >39°C
  No Referent group
  Yes 1.86 (1.13–3.07) .014
 Unable to walk unaided
  No Referent group
  Yes 2.77 (1.92–4.01) <.001
Tuberculosis symptoms
 Fever
  No Referent group
  Yes 1.07 (.67–1.69) .783
 Night sweats
  No Referent group
  Yes 1.18 (.81–1.72) .384
 Weight loss
  No Referent group
  Yes 3.08 (1.54–6.17) .002
Increasing number of  
tuberculosis symptoms
1.28 (1.01–1.64) .041
Radiographic assessment of tuberculosis
 Unlikely Referent group
 Possible 2.13 (1.00–4.54) .052
 Likely 11.01 (4.92–24.66) <.001
Laboratory investigations
 Hemoglobin, g/dLb 0.69 (.63–.76) <.001
 WCC, ×109/Lc 0.90 (.87–.93) <.001





Table  1.  Baseline Characteristics of 484 Seriously Ill Human 
Immunodeficiency Virus–Infected Participants Presenting With a Cough of 
Any Duration and ≥1 World Health Organization Danger Sign
Characteristic No. (%) or Median  
(25th–75th Percentile)
Baseline variables
 Age, y 36 (30–42)
 Sex, female 317 (65.5)
 Body mass indexa, kg/m2 20 (18–39)
 CD4 countb, cells/µL 89 (34–210)
 Cough durationc, d 14 (7–21)
 Cough duration ≥14 d 296 (61.2)
 Using ART 171 (35.3)
 Duration on ART, y 2.3 (0.2–5)
 Previous tuberculosis 236 (48.8)
 Sputum inductiond 312 (65.7)
WHO danger signs
 Respiratory rate >30 breaths/min 315 (65.1)
 Heart rate >120 beats/min 383 (79.1)
 Temperature >39°C 81 (16.7)
 Unable to walk unaided 259 (53.5)
Tuberculosis symptoms
 Fevere 394 (81.6)
 Night sweatsf 314 (65.3)
 Weight loss 442 (91.3)
Laboratory investigations
 Hemoglobing g/dL 9.5 (7.8–11.2)
 WCCh, ×109/L 8.6 (5.6–13.0)
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inpatients fulfilling the criteria of the 2007 WHO algorithm for 
seriously ill HIV-infected patients. In 2016 (when enrollment 
into our study was completed), the WHO updated the algo-
rithm by including classic tuberculosis symptoms and the Xpert 
MTB/RIF assay, and by making cough of any duration an inclu-
sion criterion [22]. We had already incorporated all of these 
features into our study; therefore, we are also able to evaluate 
the updated WHO algorithm, but it should be noted that cough 
is no longer a requirement. We developed a clinical predic-
tion rule with good diagnostic performance for tuberculosis 
using 6 variables, all of which are readily obtainable in most 
resource-constrained settings. The most significant predictors 
of tuberculosis were a radiologist assessment of likely tubercu-
losis on chest radiograph and anemia, while a raised WCC was 
a strong negative predictor of tuberculosis. The classic tuber-
culosis symptoms added no discriminatory value in diagnos-
ing tuberculosis. Scores of 3 or 4 in our clinical prediction rule 
could be used to start empiric antituberculosis therapy in seri-
ously ill patients as the sensitivity of these scores is around 90%. 
However, no single feature of our clinical prediction rule should 
be used in decisions to treat empirically for tuberculosis. The 
Xpert MTB/RIF assay, which has not previously been evaluated 
in seriously ill inpatients, had a high sensitivity of 86.3% in our 
participants. Implementation of our clinical prediction rule in 
resource-constrained settings could augment the 2016 WHO 
algorithm, inform the development of future algorithms, and 
ensure timely initiation of empiric antituberculosis treatment 
in seriously ill HIV-infected patients.
The 2007 WHO algorithm for seriously ill patients requires 
cough duration of 2–3 weeks. Although we found that cough 
duration of ≥14 days was predictive of tuberculosis, 28.6% of 
participants with confirmed tuberculosis had cough duration 
<14 days. Most of the data on cough duration of >14 days as 
a trigger for tuberculosis investigations are from studies of 
ambulatory patients and may not be generalizable to seriously 
ill inpatients. Two African studies found a high prevalence of 
tuberculosis among inpatients presenting acutely with pneumo-
nia [7, 8]. These findings together with ours suggest that any 
cough duration was an appropriate improvement made in the 
2016 WHO algorithm for the diagnosis of tuberculosis among 
seriously ill patients.
The classic tuberculosis symptoms fever and weight loss 
were sensitive, but not specific for the diagnosis of tuberculosis 
among HIV-infected inpatients with negative sputum smears 
[23]. The differential diagnosis in HIV-infected inpatients with 
cough and danger signs is wide, and many of these disorders 
and/or advanced HIV disease could reduce the diagnostic utility 
of the classic tuberculosis symptoms, which could explain why 
these were not independently associated with tuberculosis in 
our study. Two of the WHO danger signs, being unable to walk 
unaided and temperature >39°C, were significant predictors of 
tuberculosis in our cohort.
The WHO has recently reiterated the importance of using 
chest radiographic assessment to facilitate the rapid initiation 
of antituberculosis therapy among seriously ill HIV-infected 
patients [24]. Our study supports this recommendation, with 
a radiologist assessment of likely tuberculosis being the strong-
est predictor of tuberculosis in our clinical prediction rule. 
Other studies of hospitalized HIV-infected participants with 
smear-negative pulmonary tuberculosis have also reported 
the diagnostic value of chest radiography [17, 23, 25, 26]. The 
commonest individual radiographic feature associated with 
culture-positive tuberculosis in our study was enlarged hilar or 
mediastinal lymph nodes. Cavitation was not a significant clin-
ical predictor of culture-positive tuberculosis, which might be 
explained by the low median CD4 count and high prevalence 
Figure 2. Upper, Calibration plot for the assessment of variables included in a 
multivariate logistic regression model aimed at establishing a clinical prediction 
rule for the diagnosis of tuberculosis among 484 seriously ill human immunodefi-
ciency virus (HIV)–infected participants presenting with a cough of any duration and 
1 or more World Health Organization (WHO) danger sign. The line shows perfect 
calibration between observed and predicted tuberculosis. Lower, Discrimination 
of the multivariate logistic regression model aimed at establishing a clinical pre-
diction rule for the diagnosis of tuberculosis among 484 seriously ill HIV-infected 
participants presenting with a cough of any duration and ≥1 WHO danger sign. 
Abbreviations: CI, confidence interval; ROC, receiver operating characteristic.
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of previous tuberculosis. Other studies of inpatients from 
high-burden settings have also reported that intrathoracic lym-
phadenopathy was a good predictor of tuberculosis, but cavita-
tion was not [25, 26].
Our finding that anemia was associated with tuberculosis is in 
keeping with other studies of inpatients and outpatients [12, 26]. 
A study from Cameroon found anemia and leukopenia to be in-
dependent predictors of extrapulmonary involvement in patients 
with pulmonary tuberculosis; many patients in our cohort had 
disseminated disease, which could explain why hemoglobin and 
WCC were good predictors of tuberculosis [13].
Sputum Xpert MTB/RIF assay performed well in our cohort, 
with a sensitivity of 86.3%, which is somewhat higher than the 
sensitivity of 79% reported in HIV-infected patients in a sys-
tematic review [10]. The high sensitivity of Xpert MTB/RIF 
assay we found could be explained by the high proportion of 
participants who had sputum induction, which increased the 
yield of Xpert MTB/RIF assay in our study (contrary to the find-
ings of a study in ambulatory patients) [27]. We found a higher 
yield of sputum culture with sputum induction than spontane-
ous sputum production, which is consistent with other studies 
[27, 28]. In view of these findings, we call for greater access to 
sputum induction in resource-constrained settings.
Our study has some limitations. First, our findings may not 
be generalizable to patients without cough or in settings with 
different prevalence of tuberculosis and other pulmonary 
opportunistic infections. Two studies evaluated the prevalence 
of culture-positive tuberculosis in HIV-infected inpatients with 
WHO danger signs and negative sputum smears, reporting 23% 
in a Ugandan study [6] (51% of whom had WHO danger signs) 
and 23% in a study from South Africa [5], which is similar to 
the 22.7% culture-positive prevalence in our participants with 
negative sputum smears, suggesting that our findings are gener-
alizable to sub-Saharan Africa. Tuberculosis is the leading cause 
of hospitalization among HIV-infected adults worldwide, with 
similar proportions in low- to middle-income countries, and 
it is thus conceivable that our findings may also be generaliz-
able outside of Africa [29]. Second, all our participants had 1 
or more WHO danger signs, which limited our ability to assess 
their value for the diagnosis of tuberculosis. Third, a specialist 
radiologist’s assessments of the chest radiographs performed 
well in our clinical prediction rule, but in resource-constrained 
settings nonspecialist doctors usually read chest radiographs 
and their interpretation is likely to be less accurate. Fourth, the 
diagnoses of bacterial pneumonia and PJP were clinical and not 
based on microbiological reference standards. We attempted 
to confirm bacterial pneumonia with blood and sputum cul-
tures, but these were almost all negative because of antibiotic 
use immediately before inclusion into our study. Fifth, the ref-
erence standard for diagnosing tuberculosis was culture, which 
is not 100% sensitive. Finally, while bootstrap resampling has 
several advantages over other internal validation methods, it 
is not enough to demonstrate the external applicability of the 
derived prediction rule. Because internal validation in general 
is optimistic, a drop in the performance of the prediction rule 
could be observed when it is applied to different settings. While 
our measure of optimism suggests that such a drop would be 
marginal, external validation, ideally conducted by different 
investigators, is needed to confirm the performance of our pre-
diction rule before wide uptake in routine practice. Strengths of 
Table  4. Clinical Prediction Rule for the Diagnosis of Culture-Positive 
Tuberculosis Among 484 Seriously Ill Human Immunodeficiency Virus–
Infected Participants Presenting With a Cough of Any Duration and ≥1 
World Health Organization Danger Sign
Variable Category Points
Cough duration ≥14 d 1
Temperature >39°C  Yes 1
Unable to walk unaided  Yes 1
Tuberculosis on chest radiograph  Possible 1
 Likely 5
Hemoglobin, g/dL  3.3–8.3 3
 8.4–10.6 2
White cell count, ×109/L  1–6.5 1
 11.2–40.4 –2
Table 5. Diagnostic Accuracy Assessment of a Clinical Prediction Rule for the Diagnosis of Culture-Positive Tuberculosis Among 484 Seriously Ill Human 
Immunodeficiency Virus–Infected Participants Presenting With a Cough of Any Duration and ≥1 World Health Organization Danger Sign
Total Score Probability of Tuberculosis Sensitivity Specificity Positive Likelihood Ratio Negative Likelihood Ratio
≤1 0.1% 100% 0.0% 1 …
2 0.2% 95.2% 28.8% 1.34 0.17
3 0.5% 92.2% 45.4% 1.69 0.17
4 1.1% 87.2% 59.3% 2.14 0.23
5 2.5% 78.6% 67.7% 2.43 0.31
6 5.6% 66.0% 80.3% 3.36 0.42
7 12.2% 50.8% 90.5% 5.35 0.54
8 24.4% 39.1% 93% 5.58 0.65
9 43.0% 31.2% 96.4% 8.67 0.71
10 63.7% 19.5% 97.9% 9.13 0.82
11 80.4% 5.9% 99.6% 13.44 0.95
12 90.5% 0.2% 100% … 1
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our study are its prospective design, the use of multiple myco-
bacterial cultures and sputum induction to establish a reference 
standard for tuberculosis, and a higher than expected number 
of tuberculosis events, which increased our power to develop a 
clinical prediction rule.
In conclusion, we developed a clinical prediction rule with 
good performance characteristics for diagnosing tuberculosis 
in seriously ill HIV-infected patients and showed that the Xpert 
MTB/RIF assay had high sensitivity. These findings, if validated 
in different settings, could contribute to the development of an 
improved algorithm for tuberculosis in seriously ill inpatients.
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Sputum	 221	 	 	 	 	 	 	 	
Blood	 86	 114	 	 	 	 	 	 	
CSFa	 5	 1	 6	 	 	 	 	 	
Lymph	
node(s)	
1	 2	 0	 2	 	 	 	 	
Ascitic	
fluid	
0	 1	 0	 0	 1	 	 	 	
Pleural	
fluid	
12	 7	 1	 0	 0	 19	 	 	
Pus	 1	 1	 1	 0	 0	 0	 1	 	
Urine	 8	 8	 1	 1	 0	 1	 0	 11	





















Variables	 β-coeficient		 95%	CI	 Wald’s	
p-value	
Cough	duration	≥14	days	 	 	 	
No	 Referent	group	
Yes	 0·80	 0·29	to	1·30	 0·002	
WHO	danger	signs		 	 	 	
Temperature	>39
o
C		 	 	 	
No	 Referent	group	
Yes	 0·57	 -0·08	to	1·22	 0·084	
Unable	to	walk	unaided		 	 	 	
No	 Referent	group	





Possible		 1·15	 0·26	to	2·04	 0·011	
Likely	 2·63	 1·69	to	3·58	 <0·001	
Laboratory	Investigations		 	 	 	
Haemoglobin	(3.3	-	8.3	g/dL)	 Referent	group	 	
Haemoglobin	(8.4	-	10.6	g/dL)	 0·73	 0·14	to	1·31	 0·016	






/L)	 0·43	 -0·17	to	1·02	 0·161	
WCC	(11.2	-	40.35	x10
9
/L)	 -0·74	 -1·35	to	-0·13	 0·017	
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